Xtandi (Enzalutamide) and Zytiga (Abiraterone) Can Be Safely Co-Administered To Maximize Treatment Response in Patients with Metastatic Castration-Resistant Prostate Cancer (MCRPC)
Xtandi and Zytiga: Maximizing Response in Prostate Cancer by Co-administration or Sequencing?
A recent study that is to be presented at ASCO, demonstrated that Xtandi and Zytiga can be safely coadministered to patients with metastatic prostate cancer in order to maximize response to treatment in patients with castration-resistant prostate cancer. There were no life-threatening side effects and most side effects were no different from when the medications administered separately. After 8 weeks, 75% of patients had undetectable testosterone levels (less than 1 pg/mL).
The importance of this study is that it demonstrates another potential treatment approach for treating patients with metastatic prostate cancer who are at high risk of death. If an incremental benefit can be achieved by co-administering two medications instead of sequencing them one after another, time can be saved which is the most limiting factor when it comes to treatment of patients with short life expectancy, typically <2 years.
More importantly, this information can be combined with other recent studies that demonstrate that response to treatment with Xtandi and Zytiga can be predicted based on molecular characteristics of prostate cancer cells including the presence or absence of androgen receptor. This will allow us to further optimize care of patients with metastatic castration-resistant prostate cancer.
- Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration-resistant prostate cancer (mCRPC). http://abstracts.asco.org/144/AbstView_144_133919.html